Vona Oncology is an early clinical-stage biopharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer. The firm's early abalyses demonstrate strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo leading the firm's principals to identify the major target of VDX-111 in TNBC having shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit. The firms near term objective is completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Longer term, the vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
